144 related articles for article (PubMed ID: 27125377)
1. Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor.
Lumb S; Fleischer SJ; Wiedemann A; Daridon C; Maloney A; Shock A; Dörner T
J Cell Commun Signal; 2016 Jun; 10(2):143-51. PubMed ID: 27125377
[TBL] [Abstract][Full Text] [Related]
2. Novel binding site for Src homology 2-containing protein-tyrosine phosphatase-1 in CD22 activated by B lymphocyte stimulation with antigen.
Zhu C; Sato M; Yanagisawa T; Fujimoto M; Adachi T; Tsubata T
J Biol Chem; 2008 Jan; 283(3):1653-1659. PubMed ID: 18024433
[TBL] [Abstract][Full Text] [Related]
3. CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation.
Sieger N; Fleischer SJ; Mei HE; Reiter K; Shock A; Burmester GR; Daridon C; Dörner T
Arthritis Rheum; 2013 Mar; 65(3):770-9. PubMed ID: 23233360
[TBL] [Abstract][Full Text] [Related]
4. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
5. Besides an ITIM/SHP-1-dependent pathway, CD22 collaborates with Grb2 and plasma membrane calcium-ATPase in an ITIM/SHP-1-independent pathway of attenuation of Ca2+i signal in B cells.
Chen J; Wang H; Xu WP; Wei SS; Li HJ; Mei YQ; Li YG; Wang YP
Oncotarget; 2016 Aug; 7(35):56129-56146. PubMed ID: 27276708
[TBL] [Abstract][Full Text] [Related]
6. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
7. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
[TBL] [Abstract][Full Text] [Related]
8. CD22 is a negative regulator of B-cell receptor signalling.
Nitschke L; Carsetti R; Ocker B; Köhler G; Lamers MC
Curr Biol; 1997 Feb; 7(2):133-43. PubMed ID: 9016707
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
10. Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients.
Fleischer V; Sieber J; Fleischer SJ; Shock A; Heine G; Daridon C; Dörner T
Arthritis Res Ther; 2015 Jul; 17(1):185. PubMed ID: 26183319
[TBL] [Abstract][Full Text] [Related]
11. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22.
Özgör L; Brandl C; Shock A; Nitschke L
Eur J Immunol; 2016 Sep; 46(9):2260-72. PubMed ID: 27352780
[TBL] [Abstract][Full Text] [Related]
12. B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation.
Fujimoto M; Kuwano Y; Watanabe R; Asashima N; Nakashima H; Yoshitake S; Okochi H; Tamaki K; Poe JC; Tedder TF; Sato S
J Immunol; 2006 Jan; 176(2):873-9. PubMed ID: 16393971
[TBL] [Abstract][Full Text] [Related]
13. The role of CD22 and other inhibitory co-receptors in B-cell activation.
Nitschke L
Curr Opin Immunol; 2005 Jun; 17(3):290-7. PubMed ID: 15886119
[TBL] [Abstract][Full Text] [Related]
14. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM
Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387
[TBL] [Abstract][Full Text] [Related]
15. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions.
Nitschke L
Immunol Rev; 2009 Jul; 230(1):128-43. PubMed ID: 19594633
[TBL] [Abstract][Full Text] [Related]
16. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment.
Haga CL; Ehrhardt GR; Boohaker RJ; Davis RS; Cooper MD
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9770-5. PubMed ID: 17522256
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
18. Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes.
Chan VW; Lowell CA; DeFranco AL
Curr Biol; 1998 May; 8(10):545-53. PubMed ID: 9601638
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
20. Differential roles of N- and C-terminal immunoreceptor tyrosine-based inhibition motifs during inhibition of cell activation by killer cell inhibitory receptors.
Bruhns P; Marchetti P; Fridman WH; Vivier E; Daëron M
J Immunol; 1999 Mar; 162(6):3168-75. PubMed ID: 10092767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
